Endocrine Abstracts

A 39-year-old man was referred to the endocrinology clinic with a suspected phaeochromocytoma. He had a history of hypertension, episodic flushing and erectile dysfunction. He denied any recreational drugs abuse. His past medical history included primary hypogonadism of unknown cause and hypertension. He was on ramipril 5 mg od, atenolol 50 mg od and susatnon injections.Clinical examination was unremarkable away from BMI of 35, facial flushing and raised...

We present, the first reported case of twins conceived by Assisted Reproductive Technology (Gamete Intra-fallopian Transfer Therapy; GIFT), both diagnosed to have Complete Androgen Insensitivity Syndrome (CAIS).Eighteen-year-old twins presented to the Endocrine clinic with primary amenorrhoea. They were conceived by GIFT and were born premature at 34 weeks and delivered by forceps. On examination, they were two 18 year olds with normal female appearance,...

Introduction: Levothyroxine is the globally preferred therapeutic compound for primary hypothyroidism. Due to expense and poor efficacy, Liothyronine is not used as first line treatment. This study was formed to answer the ESE’s recent call for data on symptomatic response to Liothyronine and predictors of that response.Method: Patients with failure of symptomatic relief on levothyroxine were invited to try Liothyronine. 23 patients were enrolled. T...

Background: Post-treatment monitoring of thyroid cancer depends on risk stratification for future recurrence or possible extra-thyroidal metastasis. Current guidance suggests that patients with favourable prognostic factors and a low likelihood of recurrence can be effectively monitored in community settings. This study explores the safety of community-based surveillance for stable low-risk thyroid cancer patients discharged from specialised thyroid clinic.<p class="abstex...

Purpose: To evaluate long-term safety and efficacy of cinacalcet in management of primary hyperparathyroidism (PHPT).Material/Methods: We retrospectively studied all patients on cinacalcet for primary hyperparathyroidism over 3 year’s period. Data was collected and analyzed for indication, daily maintenance dose, tolerability, biochemical effect at 3, 6 and 12 months, effect on bone mineral density and renal stone disease. This study excluded those ...

Background: The treatment goal in primary hyperparathyroidism (PHPT) is the achievement of biochemical control and prevention of target organ complications. Parathyroidectomy is the current recommended intervention to cure the disease. However, Cinacalcet is an alternative medical treatment for subgroup of patients in whom surgery is deemed inappropriate, those with recurrent disease, and as bridging therapy for delayed operation particularly in recent COVID pandemic. Current ...

This is a case of a patient diagnosed with small cell lung carcinoma after presenting with severe hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) who was readmitted 7 months later with refractory hypokalemia and hyperglycaemia due to ectopic adrenocorticotrophic hormone secretion (EAS). A 65 year-old man presented in November 2018 with symptoms of nausea, vomiting, headaches and blurred vision. On examination he was clinically euvolemic. La...

Introduction: Parathyroid cancer is a rare endocrine malignancy and constitutes 0.005% of all cancers. It can recur in 50% of cases. The first recurrence commonly occurs within 3 years of the original diagnosis. Hypercalcaemia is the main cause of morbidity and mortality. We present a case of a 62-year-old male patient who had an atypical lung nodule recurrence with normal calcium and PTH levels, six years following resection of a functioning parathyroid cancer.<p class="a...

Abstract withdrawn....

Abstract withdrawn....